INTRODUCTION AND OBJECTIVES: Episode based, or "bundled," payment models hold a single entity accountable for all spending in the 90-day post-op period. Given its volume and financial impact, radical prostatectomy (RP) is likely to be a focus of future policy expansions. However, non-index hospital readmissions (NIHRs) would be outside the financially responsible provider's control. We compared causes and costs of index and non-index hospital readmissions (IHRs vs. NIHRs) following RP.
INTRODUCTION AND OBJECTIVES: Multi-parametric resonance imaging (mpMRI) has emerged to improve disease riskstratification and decrease number of repeat biopsies in men on prostate cancer active surveillance (AS). However, the impact of mpMRI on cost of AS has not been established. Thus, we characterized the impact of mpMRI on cost of AS in the Medicare population.
METHODS: Using SEER-Medicare data we identified men !66 years with localized grade group I-II prostate cancer diagnosed from [2008] [2009] [2010] [2011] [2012] [2013] . With an established algorithm, we classified men into active surveillance with and without mpMRI. We then determined costs of surveillance in each group using inflation-adjusted Medicare payments for surveillance-related procedures and their sequelae (i.e. PSA tests, prostate biopsies, post-biopsy complications and mpMRIs). Multivariable median regression compared cost and proceduralintensity for men who received mpMRI and those who did not.
RESULTS: We identified 9,081 men on AS with median follow up of 45 months (IQR 29-64 months). 7,856 (87%) men did not receive a mpMRI and 1,225 (13%) did. On multivariable median regression, receipt of mpMRI was associated with an additional $449 (95%CI $391-$507) in Medicare payments per year. Younger age, treatment in the west or northeast, greater population density, and treatment later in the study period were associated with increased cost of AS.
CONCLUSIONS: Among Medicare beneficiaries on AS, mpMRI is associated with additional annual cost to Medicare. MpMRI may be a marker of more stringent AS, which is likely more costly than watchful waiting. Future studies are needed to determine optimal use of mpMRI during AS to maximize value.
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Kevin Wymer*, Vidit Sharma, Bijan Borah, Rochester, MN; James Catto, Sheffield, United Kingdom; R. Houston Thompson, R. Jeffrey Karnes, Stephen Boorjian, Rochester, MN INTRODUCTION AND OBJECTIVES: Despite increasing emphasis on value-based care, the cost-effectiveness of prostate cancer (PCa) management options has not been compared using prospective clinical trial data. The prostate testing for cancer and treatment (ProtecT) trial demonstrated no difference in survival for patients with primarily low/intermediate risk PCa randomized to active surveillance (AS), external beam radiotherapy (RT), or radical prostatectomy (RP). While AS had the lowest complication rate, AS also had a higher rate of metastasis compared to RT or RP. We herein compared the cost-effectiveness among the management arms of ProtecT.
METHODS: A Markov decision analytic model was created to compare the cost-effectiveness of AS, RP, and RT based on ProtecT outcomes; specifically, 6 year quality of life data (perioperative complications, urinary, sexual, and bowel symptoms) and 10 year oncologic data (biochemical recurrence, metastases, and all-cause Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e417
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